Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Characterization of bortezomib-adapted I-45 mesothelioma cells

Figure 2

Expression of proteasome subunit proteins, proteasome activity, and ubiquitinated protein accumulation. A: I-45 and I-45-BTZ-R cells were treated with 40 nM bortezomib for 24, 48, or 72 hours. Expression of the proteasome subunits β1, β2, and β5 was analyzed by Western blot analysis. B: I-45 and I-45-BTZ-R cells were treated with 40 nM bortezomib for 8, 24, or 30 hours. Proteasome chymotrypsin-like activity was determined by measuring the release of the fluorophore 7-amido-4-methylcoumarin (AMC) from the substrate N-succinyl-Leu-Val-Tyr-7 (LLVY) amido-4-methylcoumarin. Values are the mean ± SD of three experiments. * p < 0.05 as compared to untreated I-45 cells. C: I-45 and I-45-BTZ-R cells were treated with 40 nM bortezomib for 24, 48, or 72 hours. Expression of ubiquinated proteins were analyzed by Western blot analysis. D: I-45-BTZ-R cells were treated with 5, 10, or 20 μM AAF-CMK with or without 40 nM bortezomib for 48 hours. Cell viability was determined following treatment using the XTT assay. Control cells were treated with PBS and their viability was set as 100%. Values are the mean ± SD of triplicate assays from two experiments.

Back to article page